Internal Emails Reveal FDA's Concerns With Voluntary Animal Antibiotic Policies


An internal FDA memo circulated last month shows the agency is mulling timeframes for animal drug sponsors to comply with new voluntary policies intended to reduce the subtherapeutic use of antibiotics in food animals, but also reveals the agency has crafted regulatory options as a fallback if the voluntary efforts fail. Another internal email reveals the agency's earlier frustration with industry, with an agency official suggesting legislation or a lawsuit would be more effective than the voluntary effort. An animal drug industry source rebuffed suggestions that the documents imply industry is not on board with FDA's voluntary antibiotic control efforts.

The documents, obtained through a Freedom of Information Act Request filed by Public Employees for Environmental Responsibility (PEER), emerge as a key House lawmaker pledges to push legislation that would require industry report antibiotic use data.

PEER said the group filed the FOIA to gauge the agency's justification for its public assertions that the animal drug industry would voluntarily cooperate in limiting subtherapeutic uses of antibiotics. FDA handed over the internal emails in recent weeks after PEER sued the agency in July for not initially responding to the FOIA request, the group said.

In a May 2011 email, William Flynn, deputy director of science policy at FDA's Center for Veterinary Medicine, said the Animal Health Institute's reaction to a then-recently filed lawsuit against FDA was “very problematic.”

“They make no reference to the fact that they are working with FDA to address this issue,” he writes, responding to an AHI statement to trade press that was also sent to FDA officials. “They simply refer to the fact that the risk is 'vanishingly small' and that the products are approved by FDA and are therefore safe (i.e, there is no problem). This type of position just reinforces the idea that legislation (or perhaps a lawsuit) is needed because FDA's plan to work with industry will not work. I think we should consider reminding AHI of this point.”

The exchange occurred when the Natural Resources Defense Council and several other groups sued FDA in May 2011 for not responding to citizen petitions and not proceeding with 1977 withdrawal hearings to remove penicillins and tetracyclines from animal feed.

AHI shared its response to trade press on the the matter with FDA's top veterinary official Bernadette Dunham, who shared it with other agency veterinary officials.

“Several risk assessments measuring the risk of various antibiotic compounds used in animal agriculture have been published in peer reviewed journals, and they uniformly find the risk to public health to be vanishingly small,” according to an excerpt of the 2011 AHI statement. “In one example, the risk of a human antibiotic treatment failure due to the use of antibiotic animals was less than that of dying from a bee sting. The lawsuit not only ignores this recent science, but also fails to cite any data or new information.”

The email exchange also occurred before FDA advanced several policies on the topic. In the following months, an August 2011 internal memo shows FDA's strategy in releasing more policies aimed at restricting antibiotics, but also recognizes the strategy's limitations such as its lack of specific timeframes and questions over whether drug sponsors would decide it is in their best interest to work cooperatively with the agency and whether FDA would collect sufficient data to measure the effectiveness of the strategy.

The agency rescinded 1977 product withdrawal hearing notices in December 2011 and issued three documents in April: final guidance on the judicious use of antibiotics in food animals, proposed regulation on veterinary oversight; and draft guidance outlining how companies can voluntarily change product labels

But an animal drug industry source tells FDA Week the FOIA documents depict a narrow view on the topic and the overall the public record shows companies support and will cooperate with FDA's efforts to remove production uses from product labels.

“I think it's being taken out of context,” said Ron Phillips, vice president of legislative and public affairs at the Animal Health Institute, in response to the Flynn email.“That discussion had to do with our statement regarding the lawsuit.” Phillips further questioned whether PEER released the entire FOIA, as the group said FDA released a “foot-thick stack of materials” but the group released only 11 pages of memos and emails.

PEER says the documents clearly show the industry is not cooperating. “These documents show that FDA’s public health strategy is to whistle past the graveyard, as more people are pushed beyond the help of medically vital drugs,” said PEER Counsel Kathryn Douglass who filed the FOIA suit. “In the foot-thick stack of materials FDA surrendered there is not a shred of evidence that industry is working to phase-out injudicious use of these drugs.”

Phillips disagreed with the conclusion saying the documents do not illustrate that either party -- FDA or animal drug companies -- are not committed to the process laid out by FDA. “I cannot say that strongly enough,” he said. “FDA is obviously committed to this. We have publicly committed to this.”

Aside from the the internal emails, three memos also lay out FDA thoughts on the voluntary process.

A memo sent last month suggests FDA outline timeframes for drug sponsor action, with the agency saying the timelines would ensure the voluntary effort is making progress and companies marketing similar products are being treated equally. When commenting on the new policies, AHI and other stakeholders questioned how FDA would ensure product label changes are done in a timely manner across product classes.

“Recognizing, however, that the voluntary approach will only work if all sponsors decide it is in their best interest to work cooperatively with the agency to achieve these goals, CVM also suggests that setting out some timeframes within which we expect to see progress toward achieving these goals,” the memo states. “These could include dates by which the sponsor: submits a letter of intent to us about how/when sponsor will remove subtherapeutic claims and change marketing status; submits supplemental application to us; notifies distributors/veterinarians about change in claims and marketing status; etc.”

The agency goes on to say the timeframes will be published in the Federal Register to “help maintain a transparent process, and will assure the public that we are making real-time progress toward our final goals. It will also help assure each company that FDA is treating all companies marketing similar products similarly.”

FDA also said the agency should further evaluate how to communicate the ramifications for missing a milestone date, how far FDA should go in “foreshadowing” regulatory action if the voluntary approach fails and regulatory actions that should be taken if the voluntary action does not achieve its intended goals. The agency's email goes on to outline available regulatory actions, but they are redacted from the document released to PEER.

Phillips noted that FDA had already outlined a broader timeline for compliance when it issued guidance on the process for implementing label changes. He said he was not surprised FDA further evaluated the matter. Within three months of the guidance's finalization, FDA requests companies notify the agency of their intentions. Within three years the agency will evaluate the approach to determine whether further action is warranted, according to the draft guide.

The documents emerge as Rep. Henry Waxman (D-CA) proposes to expand drug company data collection and reporting, with the Pew Campaign on Human Health and Industrial Farming saying the lawmaker's promised bill would help monitor the progress of FDA's new policies (see related story). -- Alaina Busch ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it )

Free Trial

Sign up for one month of free, no-obligation access to,com_trialuser/code,home/?S=JD

Written by:
less on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.